Prediction of Childhood Epilepsy Outcome in Bangladesh

Randomised controlled trial of the use of phenobarbitone and carbamazepine in childhood epilepsy in Bangladesh with particular reference to behavioural side effects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Epilepsy Brain Diseases Central Nervous System Diseases Nervous System Diseases

Age range

2 year–16 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Children's Hospital Dhaka (Shishu) Bangladesh., Sher-e-Bangla Nagar, Dhaka 1207, Bangladesh

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Active epilepsy
Aged 2-15 years

Exclusion criteria

Excluded absence
Myoclonic and malignant epilepsy syndromes
Major motor and cognitive impairments
Those currently receiving antiepilepsy drugs.

Treatment and study plan

phenobarbitone

Drug

carbamazepine

Drug

Sponsors and collaborators

Lead sponsor

Institute of Child Health

Other

Registry information

Important dates

First posted: Sep 28, 2006
Registry last updated: Dec 25, 2006

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed